DoD Tuberous Sclerosis Complex Exploration-Hypothesis Development Award
The summary for the DoD Tuberous Sclerosis Complex Exploration-Hypothesis Development Award grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.
DoD Tuberous Sclerosis Complex Exploration-Hypothesis Development Award: The EHDA supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the TSC research field. The studies supported by this award mechanism are expected to lay the groundwork for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design. Preliminary and/or published data are not required.
The proposed research project must be innovative, feasible, and supported by strong rationale. Innovative research may introduce a novel paradigm, challenge existing paradigms, look at existing problems from novel perspectives, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative and is not consistent with the intent of this award mechanism. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly articulate how the proposed research project is innovative in the field of TSC.
Research involving human subjects and human anatomical substances is permitted; however, studies must be exempt under Title 32 of the Code of Regulations, Part 219.101(b) (32 CFR 219.101(b)) or eligible for expedited review (32 CFR 219.110 or 21 CFR 56.110). Exemption or expedited status is first determined by the Institutional Review Board (IRB) of record. Investigators must review their institutional requirements and guidelines for filing with the IRB for exempt or expedited status. Studies that do not qualify for exempt or expedited status will be administratively withdrawn. Clinical trials are not allowed under this Program Announcement/Funding Opportunity. For more information on clinical trials and clinical research overall, a Human Subject Resource Document is provided on the electronic Biomedical Research Application Portal (eBRAP) system at https://ebrap.org/eBRAP/public/Program.htm. PIs wishing to apply for funding for a pilot clinical trial should utilize the FY16 TSCRP Pilot Clinical Trial Award mechanism (Funding Opportunity Number: W81XWH-16-TSCRP-PCTA).
The proposed research project must be innovative, feasible, and supported by strong rationale. Innovative research may introduce a novel paradigm, challenge existing paradigms, look at existing problems from novel perspectives, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative and is not consistent with the intent of this award mechanism. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly articulate how the proposed research project is innovative in the field of TSC.
Research involving human subjects and human anatomical substances is permitted; however, studies must be exempt under Title 32 of the Code of Regulations, Part 219.101(b) (32 CFR 219.101(b)) or eligible for expedited review (32 CFR 219.110 or 21 CFR 56.110). Exemption or expedited status is first determined by the Institutional Review Board (IRB) of record. Investigators must review their institutional requirements and guidelines for filing with the IRB for exempt or expedited status. Studies that do not qualify for exempt or expedited status will be administratively withdrawn. Clinical trials are not allowed under this Program Announcement/Funding Opportunity. For more information on clinical trials and clinical research overall, a Human Subject Resource Document is provided on the electronic Biomedical Research Application Portal (eBRAP) system at https://ebrap.org/eBRAP/public/Program.htm. PIs wishing to apply for funding for a pilot clinical trial should utilize the FY16 TSCRP Pilot Clinical Trial Award mechanism (Funding Opportunity Number: W81XWH-16-TSCRP-PCTA).
Federal Grant Title: | DoD Tuberous Sclerosis Complex Exploration-Hypothesis Development Award |
Federal Agency Name: | Dept of the Army USAMRAA |
Grant Categories: | Science and Technology |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | W81XWH-16-TSCRP-EHDA |
Type of Funding: | Cooperative Agreement, Grant |
CFDA Numbers: | 322045 |
CFDA Descriptions: | Military Medical Research and Development |
Current Application Deadline: | Jul 18, 2016 |
Original Application Deadline: | Jul 18, 2016 |
Posted Date: | May 9, 2016 |
Creation Date: | May 9, 2016 |
Archive Date: | Aug 17, 2016 |
Total Program Funding: | $1,600,000 |
Maximum Federal Grant Award: | none |
Minimum Federal Grant Award: | none |
Expected Number of Awards: | 5 |
Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
- Grant Announcement Contact
- CDMRP Help Desk
Phone: 301-682-5507
Email: [email protected]
CDMRP Help Desk
Dept. of the Army -- USAMRAA 301-619-7144